Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?

Matrix Biology

Volumn 51, Issue , 2016, Pages 26-36

  Jimenez, Sergio A ^a,b   Piera Velazquez, Sonsoles ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

EndoMT; Endothelial cell; Fibrosis; Interstitial lung disease; Myofibroblast; Pulmonary arterial hypertension; Pulmonary fibrosis; Systemic Sclerosis

Indexed keywords

CAVEOLIN 1; ENDOTHELIN 1; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

CELL HYPOXIA; CELL TRANSFORMATION; DISEASE ASSOCIATION; ENDOTHELIAL TO MESENCHYMAL TRANSITION; ENDOTHELIUM CELL; HUMAN; LUNG FIBROSIS; LUNG PARENCHYMA; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC SCLEROSIS; WNT SIGNALING PATHWAY; COMPLICATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENETICS; PATHOLOGY;

ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; MYOFIBROBLASTS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 84957900315     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.01.012     Document Type: Review

References (120)

1. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 2007, 117:557-567.
2. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N. Engl. J. Med. 2009, 360:1989-2003.
3. Matucci-Cerinic M., Kahaleh B., Wigley F.M. Systemic Sclerosis (scleroderma, SSc) is a vascular disease. Arthritis Rheum. 2013, 65:1953-1962.
4. Jimenez S.A., Derk C.T. Following the molecular pathways toward an understanding of the pathogenesis of Systemic Sclerosis. Ann. Intern. Med. 2004, 140:37-50.
5. Katsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis. Annu. Rev. Pathol. 2011, 6:509-537.
6. Pattanaik D., Brown M., Postlethwaite B.C., et al. Pathogenesis of systemic sclerosis. Front. Immunol. 2015, 6:272.
7. Stern E.P., Denton C.P. The pathogenesis of systemic sclerosis. Rheum. Dis. Clin. N. Am. 2015, 41:367-382.
8. Veraldi K.L., Hsu E., Feghali-Bostwick C.A. Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Curr. Rheumatol. Rep. 2010, 12:19-25.
9. Herzog E.L., Mathur A., Tager A.M., et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. Arthritis Rheumatol. 2014, 66:1967-1978.
10. Tan A., Denton C.P., Mikhailidis D.P., et al. Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review. Clin. Exp. Rheumatol. 2011, 29(2 Suppl. 65):S66-S74.
11. Wells A.U., Margaritopoulos G.A., Antoniou K.M., et al. Interstitial lung disease in systemic sclerosis. Semin. Respir. Crit. Care Med. 2014, 35:213-221.
12. Sung Y.K., Chung L. Connective tissue disease-associated pulmonary arterial hypertension. Rheum. Dis. Clin. N. Am. 2015, 41:295-313.
13. Krieg T., Abraham D., Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res. Ther. 2007, 9(Suppl. 2):S4.
14. Abraham D.J., Eckes B., Rajkumar V., et al. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr. Rheumatol. Rep. 2007, 9:136-143.
15. Beon M., Harley R.A., Wessels A., et al. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin. Exp. Rheumatol. 2004, 22:733-742.
16. Watsky M.A., Weber K.T., Sun Y., et al. New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int. Rev. Cell Mol. Biol. 2010, 282:165-192.
17. Gilbane A.J., Denton C.P., Holmes A.M. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res. Ther. 2013, 15:215.
18. Kendall R.T., Feghali-Bostwick C.A. Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol. 2014, 5:123.
19. Gabbiani G. The myofibroblast: a key cell for wound healing and fibrocontractive diseases. Prog. Clin. Biol. Res. 1981, 54:183-194.
20. Kirk T.Z., Mark M.E., Chua C.C., et al. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J. Biol. Chem. 1995, 270:3423-3428.
21. Hinz B., Phan S.H., Thannickal V.J., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 2012, 180:1340-1355.
22. Kis K., Liu X., Hagood J.S. Myofibroblast differentiation and survival in fibrotic disease. Expert Rev. Mol. Med. 2011, 23(13):e27.
23. Hu B., Phan S.H. Myofibroblasts. Curr. Opin. Rheumatol. 2013, 25:71-77.
24. RG W., DE D. Matrix elasticity, cytoskeletal tension, and TGF-beta: the insoluble and soluble meet. Sci. Signal. 2008, 1(10):pe13. 10.1126/stke. 110pe13.
25. Hinz B. The extracellular matrix and transforming growth factor-β1: tale of a strained relationship. Matrix Biol. 2015, 47:54-65.
26. Hinz B., Phan S.H., Thannickal V.J., et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 2007, 170:1807-1816.
27. McAnulty R.J. Fibroblasts and myofibroblasts: their source, function and role in disease. Int. J. Biochem. Cell Biol. 2007, 39:666-671.
28. Falke L.L., Gholizadeh S., Goldschmeding R., et al. Diverse origins of the myofibroblast-implications for kidney fibrosis. Nat. Rev. Nephrol. 2015, 11:233-244.
29. Poslethwaite A.E., Shigemitsu H., Kanagat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr. Opin. Rheumatol. 2004, 16:733-738.
30. Strieter R.M., Keeley E.C., Hughes M.A., et al. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J. Leukoc. Biol. 2009, 86:1111-1118.
31. Herzog E.L., Bucala R. Fibrocytes in health and disease. Exp. Hematol. 2010, 38:548-556.
32. Bellini A., Mattoli S. The role of the fibrocytes, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. lnvest. 2007, 87:858-870.
33. Humphreys B.D., Lin S.L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., et al. Fate tracing reveals the pericyte and not epithelial origin on myofibroblasts in kidney fibrosis. Am. J. Pathol. 2010, 176:85-97.
34. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15:178-196.
35. Kramann R., Schneider R.K., DiRocco D.P., et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015, 16:51-66.
36. Arciniegas E., Neves C.Y., Carrillo L.M., et al. Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium 2005, 12:193-200.
37. Piera-Velazquez S., Li Z., Jimenez S.A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. 2011, 179:1074-1084.
38. Zeisberg E.M., Taranavski O., Zeisberg M., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13:952-961.
39. Goumans M.J., van Zonneveld A.J., ten Dijke P. Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis?. Trends Cardiovasc. Med. 2008, 18:293-298.
40. Zeisberg E.M., Potenta S.E., Sugimoto H., et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 2008, 19:2282-2287.
41. Li J., Qu X., Bertman J.F. Review: endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrology (Carlton) 2010, 15:507-512.
42. LeBleu V.S., Taduri G., O'Connell J., et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 2012, 19:1047-1053.
43. Zeisberg M., Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am. J. Physiol. Cell Physiol. 2013, 304:C216-C225.
44. Lin F., Wang N., Zhang T.C. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life 2012, 64:717-723.
45. Rieder F., Kessler S.P., West G.A., et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of interstitial fibrosis. Am. J. Pathol. 2011, 179:2660-2673.
46. Yoshimatsu Y., Watabe T. Roles of TGF-β signals in endothelial-mesenchymal transition during cardiac fibrosis. Int. J. Inflamm. 2011, 724080.
47. Cooley B.C., Nevado J., Mellad J., et al. TGF-β signaling mediates endothelial-to mesenchymal transition (EndoMT) during vein graft remodeling. Sci. Transl. Med. 2014, 6(27):ra 34.
48. Kitao A., Sato Y., Sawada-Kitamura S., et al. Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am. J. Pathol. 2009, 175:616-626.
49. Ramirez D.M., Ramirez M.R., Reginato A.M., et al. Molecular and cellular mechanisms of heterotopic ossification. Histol. Histopathol. 2014, 29:1281-1285.
50. Mintet E, Rannou E, Buard V, et al. (Jul 14 2015). Identification of endothelial-to-mesenchymal transition as a potential participant in radiation proctitis. Am. J. Pathol. doi: . (pii: S0002-9440(15)00329-6. [Epub ahead of print]). doi:10.1016/l.ajpath.2015.04.028.
51. Verrecchia F., Mauviel A., Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun. Rev. 2006, 5:563-569.
52. Varga J., Whitfield M.L. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front. Biosci. (Schol. Ed.) 2009, 1:226-235.
53. Jiménez S.A., Castro S.V., Piera-Velázquez S. Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. Curr. Rheumatol. Rev. 2010, 6:283-294.
54. Lafyatis R. Transforming growth factor β-at the centre of systemic sclerosis. Nat. Rev. Rheumatol. 2014, 10:706-719.
55. Goumans M.J., Liu Z., ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009, 19:116-127.
56. Medici D., Potenta S., Kalluri R. Transforming growth factor-β2 promotes Snail-mediated endothelial mesenchymal transition through convergence of Smad-dependent and Smad-independent signaling. Biochem. J. 2011, 433:515-520.
57. van Meeteren L.A., ten Dijke P. Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res. 2012, 347:177-186.
58. Piera-Velazquez S., Jimenez S.A. Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 2012, 5(Suppl. 1):S7.
59. Vandewalle C., Van Roy F., Berx G. The role of the ZEB family of transcription factors in development and disease. Cell. Mol. Life Sci. 2009, 66:773-787.
60. Li Z., Jimenez S.A. Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum. 2011, 63:2473-2483.
61. Gvaramia D., Blaauboer M.E., Hanemaaijer R., et al. Role of caveolin-1 in fibrotic diseases. Matrix Biol. 2013, 32:307-315.
62. Miyasato S.K., Loeffler J., Shohet R., et al. Caveolin-1 modulates TGF-β1 signaling in cardiac remodeling. Matrix Biol. 2011, 30:318-329.
63. Del Galdo F., Sotgia F., de Almeida C.J., et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008, 58:2854-2865.
64. Tourkina E., Richard M., Gööz P., et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L843-L861.
65. Wang X.M., Zhang Y., Kim H.P., et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 2006, 203:2895-2906.
66. Jasmin J.F., Mercier I., Dupuis J., et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006, 114:912-920.
67. Li Z., Wermuth P.J., Benn B.S., et al. Caveolin-1 deficiency induces spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro. Am. J. Pathol. 2013, 182:325-331.
68. Abraham D.J., Vancheeswaran R., Dashwood M.R., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 1997, 151:831-841.
69. Xu S., Denton C.P., Holmes A., et al. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J. Cardiovasc. Pharmacol. 1998, 31:S360-S363.
70. Leask A. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis. Pharmacol. Res. 2011, 63:502-503.
71. Widyantoro B., Emoto N., Nakayama K., et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010, 121:2407-2418.
72. Cipriani P., Di Benedetto P., Ruscitti P., et al. The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-β and may be blocked by macitentan, a dual endothelin-1 receptor antagonist. J. Rheumatol. Aug 15 2015, (pii: jrheum.150088. [Epub ahead of print]).
73. Louvi A., Artavanis-Tsakonas S. Notch and disease: a growing field. Semin. Cell Dev. Biol. 2012, 23:473-480.
74. Penton A.L., Leonard L.D., Spinner N.B. Notch signaling in human development and disease. Semin. Cell. Dev. Biol. 2012, 23:450-457.
75. Chari N.S., McDonnell T.J. The sonic hedgehog signaling network in development and neoplasia. Adv. Anat. Pathol. 2007, 14:344-352.
76. Briscoe J., Thérond P.P. The mechanisms of hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 2013, 14:416-429.
77. Beyer C., Distler J.H. Morphogen pathways in systemic sclerosis. Curr. Rheumatol. Rep. 2013, 15:299.
78. Beyer C., Dees C., Distler J.H. Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Arch. Dermatol. Res. 2013, 305:1-8.
79. Distler A., Lang V., Del Vecchio T., et al. Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann. Rheum. Dis. 2014, 73:1264-1268.
80. Noseda M., McLean G., Niessen K., et al. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ. Res. 2004, 94:910-917.
81. Niessen K., Fu Y., Chang L., et al. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J. Cell Biol. 2008, 182:315-325.
82. Chang A.C., Fu Y., Garside V.C., et al. Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase. Dev. Cell 2011, 21:288-300.
83. Fu Y., Chang A., Chang L., et al. Differential regulation of transforming growth factor beta signaling pathways by Notch in human endothelial cells. J. Biol. Chem. 2009, 284:19452-19462.
84. Ding H., Zhou D., Hao S., et al. Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J. Am. Soc. Nephrol. 2012, 23:801-813.
85. Syn W.K., Jung Y., Omenetti A., et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137:1478-1488.
86. Fabian S.L., Penchev R.R., Jacques B.S., et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am. J. Pathol. 2012, 180:2935-2951.
87. Jung I.H., Jung D.E., Park Y.N., et al. Aberrant Hedgehog ligands induce progressive pancreatic fibrosis by paracrine activation of myofibroblasts and ductular cells in transgenic zebrafish. PLoS ONE 2011, 6:e27941. (Epub 2011 Dec 2).
88. Bolaños A.L., Milla C.M., Lira J.C., et al. Role of Sonic Hedgehog in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 303:L978-L990.
89. Horn A., Palumbo K., Cordazzo C., et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012, 64:2724-2733.
90. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149:1192-1205.
91. Niehrs C. The complex world of WNT receptor signaling. Nat. Rev. Mol. Cell Biol. 2012, 13:767-779.
92. Lafyatis R. Connective tissue disease: SSc-fibrosis takes flight with Wingless inhibition. Nat. Rev. Rheumatol. 2012, 8:441-442.
93. Wei J., Fang F., Lam A.P., et al. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012, 64:2734-2745.
94. Beyer C., Schramm A., Akhmetshina A., et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann. Rheum. Dis. 2012, 71:761-767.
95. Dees C., Schlottmann I., Funke R., et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann. Rheum. Dis. 2014, 73:1232-1239.
96. Lam A.P., Flozak A.S., Russell S., et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am. J. Respir. Cell Mol. Biol. 2011, 45:915-922.
97. Aisagbonhi O., Rai M., Ryzhov S., et al. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. Dis. Model Mech. 2011, 4:469-483.
98. Li L., Chen L., Zang J., et al. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease. Metabolism 2015, 64:597-610.
99. Cheng S.L., Shao J.S., Behrmann A., et al. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1679-1689.
100. Semenza G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408.
101. Lokmic Z., Musyoka J., Hewitson T.D., et al. Hypoxia and hypoxia signaling in tissue repair and fibrosis. Int. Rev. Cell Mol. Biol. 2012, 296:139-185.
102. Hasse V.H. Pathophysiological consequences of HIF activation; HIF as a modulator of fibrosis. Ann. N. Y. Acad. Sci. 2009, 1177:57-65.
103. Higgins D.F., Kimura K., Iwano M., et al. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008, 7:1128-1132.
104. Ruthenborg R.J., Ban J.J., Wazir A., et al. Regulation of wound healing and fibrosis by hypoxia and hypoxia-inducible factor-1. Mol. Cells 2014, 37:637-643.
105. Coople B.L., Bai S., Burgoon L.D., et al. Hypoxia-inducible factor-1α regulates the expression of genes in hypoxia hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 2011, 31:230-244.
106. Sánchez-Elsner T., Botella L.M., Velasco B., et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 2001, 276:38527-38535.
107. Sun S., Ning X., Zhang Y., et al. Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int. 2009, 75:1278-1287.
108. Higgins D.F., Kimura K., Bernhardt W.M., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 2007, 117:3810-3820.
109. Xu X., Tan X., Tampe B., et al. Snail is a direct target of hypoxia-inducible factor 1α (HIF1α) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. J. Biol. Chem. 2015, 290:16653-16664.
110. Choi S.H., Hong Z.Y., Nam J.K., et al. A hypoxia-induced vascular endothelial-to-mesenchymal transition in development of radiation-induced pulmonary fibrosis. Clin. Cancer Res. 2015, 21:3716-3726.
111. Hashimoto N., Phan S.H., Imaizumi K., et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2010, 43:161-172.
112. Good R.B., Gilbane A.J., Trinder S.L., et al. Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. Am. J. Pathol. 2015, 185:1850-1858.
113. Moore-Morris T., Guimarães-Camboa N., Banerjee I., et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 2014, 124:2921-2934.
114. Moore-Morris T., Guimarães-Camboa N., Yutzey K.E., et al. Cardiac fibroblasts: from development to heart failure. J. Mol. Med. (Berl.) 2015, 93:823-830.
115. Ali S.R., Ranjbarvaziri S., Talkhabi M., et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 2014, 115:625-635.
116. Arciniegas E., Frid M.G., Douglas I.S., et al. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L1-L8.
117. Ranchoux B., Antigny F., Rucker-Martin C., et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015, 131:1006-1018.
118. Xiong J. To be EndoMT or not to be, that is the question in pulmonary hypertension. Protein Cell 2015, 6:547-550.
119. Jimenez S.A. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol. Sep 23 2013, 835948. 10.1155/2013/835948.
120. Mendoza F., Piera-Velazquez S., Farber J., et al. Endothelial cells expressing endothelial and mesenchymal cell gene products in Systemic Sclerosis-associated interstitial lung disease lung tissues. Arthritis Rheumatol. 2016, 68:210-217.